Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer.

Academic Article

Abstract

  • Multiple studies have reported that analysis of serum and other bodily fluids using surface enhanced laser desorption/ionization time of flight mass spectroscopy (SELDI-TOF-MS) can identify a "fingerprint" or "signature" of spectral peaks that can separate patients with a specific disease from normal control patients. Ultimately, classification by SELDI-TOF-MS relies on spectral differences in position and amplitude of resolved peaks. Since the reproducibility of quantitation, resolution and mass accuracy of the SELDI-TOF-MS, or any high throughput mass spectrometric technique, has never been determined this method has come under some skepticism as to its clinical usefulness. This manuscript describes a detailed design of a three-phase study to validate the clinical usefulness of SELDI-TOF-MS in the identification of patients with prostatic adenocarcinoma (PCA). At the end of this validation study, the usefulness of the general SELDI-TOF-MS approach to identifying patients with PCA will be demonstrated and how it compares with PCA diagnosis by measuring prostate specific antigen.
  • Published In

  • Disease Markers  Journal
  • Keywords

  • Adenocarcinoma, Algorithms, Blood Proteins, Clinical Trials as Topic, Humans, Male, Prostatic Neoplasms, Research Design, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Author List

  • Grizzle WE; Adam B-LL; Bigbee WL; Conrads TP; Carroll C; Feng Z; Izbicka E; Jendoubi M; Johnsey D; Kagan J
  • Start Page

  • 185
  • End Page

  • 195
  • Volume

  • 19
  • Issue

  • 4-5